Abstract Number: 0765 • ACR Convergence 2022
The Impact of Immunomodulating Treatment on the Immunogenicity of COVID-19 Vaccines in Patients with Immune-mediated Inflammatory Rheumatic Diseases Compared to Healthy Controls. a Swedish Nationwide Study (COVID19-REUMA)
Background/Purpose: The aim of the study was to elucidate antibody responses after vaccination with two doses of COVID-19 vaccines in patients with inflammatory rheumatic diseases…Abstract Number: 0791 • ACR Convergence 2022
Immunogenicity and Safety of a Three-dose SARS-CoV-2 Vaccination Strategy in Patients with Immune-mediated Inflammatory Diseases on Immunosuppressive Therapy
Background/Purpose: Humoral vaccine responses to SARS-Cov-2 vaccines are impaired and short lasting in patients with immune-mediated inflammatory diseases (IMIDs). Concerns have been raised regarding their…Abstract Number: 0913 • ACR Convergence 2022
Impact of Disease-modifying Antirheumatic Drugs on Immunogenicity to COVID-19 Vaccine in Patients with Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk of infection compared to healthy subjects (1). This is because of a multifactorial complex…Abstract Number: 1293 • ACR Convergence 2022
Is Virtual Care Here to Stay? : Rheumatology Patients’ Satisfaction in Early vs Late Pandemic
Background/Purpose: The COVID-19 pandemic has dramatically changed the delivery of healthcare, with virtual care becoming the new standard. In the early stages of the pandemic,…Abstract Number: 1762 • ACR Convergence 2022
Stability of Cell Bound Complement Activation Products (CB-CAPs), Multianalyte Assay Panel (MAP) with Algorithm, and Other Autoimmune Biomarkers Among Clinical Patients Throughout the SARS-CoV-2 Pandemic and Vaccination Campaigns
Background/Purpose: COVID-19 can cause autoantibody signatures in severely ill patients, and widespread emerging post-acute sequelae of SARS-CoV-2 (PASC) share many symptoms consistent with rheumatologic involvement…Abstract Number: 1933 • ACR Convergence 2022
PECOS (Pediatric SARS-CoV-2 MIS-C Long-term Outcomes Study): Preliminary Results
Background/Purpose: The long-term complications of SARS-CoV-2 and MIS-C in children are unknown. PECOS, a joint study at the National Institutes of Health (NIH) Clinical Center…Abstract Number: 2249 • ACR Convergence 2022
Impact of Interstitial Lung Disease on COVID-19 Severity Among Patients with Rheumatoid Arthritis: A Multicenter Comparative Study
Background/Purpose: Rheumatoid arthritis (RA) has been associated with severe COVID-19, but few studies have investigated outcomes in RA phenotypes such as interstitial lung disease (RA-ILD),…Abstract Number: 0211 • ACR Convergence 2022
Determinants of COVID-19 Vaccine Hesitancy in a Predominantly Black Population with Cutaneous Lupus Erythematosus
Background/Purpose: Due to demographic and disease-related factors, patients with lupus are deemed to be more vulnerable to COVID-19 infection than the general population, but they…Abstract Number: 0702 • ACR Convergence 2022
Fourth SARS-CoV-2 Vaccine Dose in Rituximab Treated Patients: An Open Label Extension Study
Background/Purpose: Humoral immune response to COVID-19 vaccination is vastly diminished in B-cell depleted patients, resulting in lower antibody titers in patients with a potential higher…Abstract Number: 0769 • ACR Convergence 2022
Heterologous Vector versus Homologous mRNA COVID-19 Booster Vaccination in Non-seroconverted Immunosuppressed Patients: A Randomized Controlled Trial
Background/Purpose: Patients under immunosuppressive therapy have a high risk for severe COVID-19 disease courses. However, efficacy of vaccination and therefore the right vaccination strategy remains…Abstract Number: 0792 • ACR Convergence 2022
Post-mRNA Vaccine Flares in Autoimmune Inflammatory Rheumatic Diseases: Results from the COronavirus National Vaccine Registry for ImmuNe Diseases SINGapore (CONVIN-SING)
Background/Purpose: Published data suggest no increased rate of flare of autoimmune inflammatory rheumatic diseases (AIIRD) after COVID-19 mRNA vaccination; however, the studies are limited by…Abstract Number: 0932 • ACR Convergence 2022
Accelerated Waning of Protective Immunity After SARS-CoV-2 mRNA Vaccination in Patients Treated with Biological and Targeted Synthetic Disease Modifying Antirheumatic Drugs
Background/Purpose: Little is known about the duration of humoral antibody levels after two SARS-CoV-2 mRNA vaccinations in patients with immunosuppression. During this ongoing global epidemic,…Abstract Number: 1326 • ACR Convergence 2022
Impact of COVID-19 Severity on Bone Mineral Density, Sarcopenia and Physical Performance Among Older Adults Following Hospitalization: A Pilot Study
Background/Purpose: Altered bone mineral density (BMD), muscle mass and physical performance has been associated with adverse outcomes, however, the effect of COVID-19 on the musculoskeletal…Abstract Number: 1763 • ACR Convergence 2022
Different Humoral but Similar Cellular Responses of Patients with Autoimmune Inflammatory Rheumatic Diseases Under Disease-modifying Anti-rheumatic Drugs After COVID-19 Vaccination
Background/Purpose: The interplay between humoral and cellular response after vaccination against SARS-CoV-2 in patients (pts.) with autoimmune inflammatory rheumatic diseases (AIRD) remains unknown. To investigate…Abstract Number: 1938 • ACR Convergence 2022
Current Approach to COVID-19 and Other Vaccinations in Children with Previous Multisystem Inflammatory Syndrome (MIS-C): An International Survey
Background/Purpose: Following the Coronavirus Disease-19 (COVID-19) pandemic outbreaks, the hyperinflammatory condition termed Multisystem Inflammatory Syndrome in Children (MIS-C) has become a healthcare issue worldwide. Since…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 35
- Next Page »